Does Emgality Prevent Migraines?
Emgality (galcanezumab), a CGRP monoclonal antibody, reduces monthly migraine days in adults with episodic or chronic migraine. In pivotal trials, patients on 240 mg monthly saw 4.7 fewer migraine days per month versus 2.8 with placebo after one month, with sustained effects over six months.[1][2] About 50-60% of patients achieved at least 50% reduction in migraine frequency.[3]
How Do Clinical Trials Back This Up?
Phase 3 trials (EVOLVE-1, EVOLVE-2 for episodic migraine; REGAIN for chronic) enrolled over 2,300 patients. Emgality cut migraine days by 4-5 versus placebo's 2-3, meeting primary endpoints (p<0.001). Responder rates were higher: 62% versus 39% for 50% reduction in episodic cases.[1][2][4] FDA approved it in 2018 based on this data for prevention in patients with 4+ migraine days monthly.
What Real-World Results Show
Post-approval studies and patient registries confirm trial findings. A 2022 analysis of 1,000+ users reported 50% reduction in 48% of cases after three months, with better outcomes in treatment-naive patients.[5] Long-term data (up to two years) shows no loss of efficacy, though 10-20% discontinue due to cost or injection issues.[6]
Compared to Other CGRP Preventives
| Drug | Monthly Migraine Day Reduction (vs Placebo) | Dosing | Key Edge |
|------|---------------------------------------------|--------|----------|
| Emgality (240 mg) | 4.7 (episodic) | Monthly subQ | High responder rate; loading dose optional |
| Aimovig (erenumab, 70/140 mg) | 3.7 | Monthly subQ | Similar efficacy; more hypertension risk |
| Ajovy (fremanezumab, 225 mg x3) | 4.6 | Monthly or quarterly | Flexible dosing |
| Vyepti (eptinezumab, 100/300 mg) | 3.9 (day 1), 8 (week 1) | IV every 3 months | Fast onset but infusion-only |
Emgality matches or exceeds peers in head-to-head meta-analyses, with no significant efficacy differences.[7]
Common Side Effects and Who It Helps Most
Injection-site reactions (18%, mostly mild) top the list; serious risks like hypersensitivity are rare (<1%). It works best for frequent migraines (8+ days/month) unresponsive to oral preventives like topiramate. Not for acute treatment or under 18.[3][8] Contraindicated in severe allergy to component.
How Patients Tolerate It Long-Term
Adherence exceeds 80% at one year in US claims data, driven by efficacy despite high cost ($700+/month pre-insurance).[9] Some report "brain fog" or constipation (5-10%), but benefits outweigh for most high-need users.
Access, Cost, and Patent Timeline
List price is $855 per dose; copays vary ($0-25 with savings cards).[10] Patent expires 2030-2033 (core US patent to 2033 per DrugPatentWatch.com[11]); biosimilars unlikely before then amid ongoing litigation.
[1] Stauffer et al., Headache 2018
[2] Detke et al., Lancet Neurol 2018
[3] FDA Label, Emgality
[4] Silberstein et al., JAMA Neurol 2019 (REGAIN)
[5] Broder et al., J Manag Care Spec Pharm 2022
[6] Ailani et al., Neurology 2021
[7] Xu et al., J Pain Res 2021 meta-analysis
[8] ClinicalTrials.gov NCT02623673
[9] Kerr et al., J Med Econ 2023
[10] GoodRx, accessed 2024
[11] DrugPatentWatch.com - Galcanezumab